Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: A continuous veno-venous hemofiltration protocol with a low concentration citrate solution

Critical Care

Volumn 16, Issue 3, 2012, Pages

  Morabito, Santo ^a   Pistolesi, Valentina ^a   Tritapepe, Luigi ^a   Zeppilli, Laura ^a   Polistena, Francesca ^a   Strampelli, Emanuela ^a   Pierucci, Alessandro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BICARBONATE; CALCIUM; CALCIUM CHLORIDE; CALCIUM ION; CITRIC ACID; HEPARIN; ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MALE; MATHEMATICAL MODEL; METABOLIC ACIDOSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGIONAL CITRATE ANTICOAGULATION; SURGICAL PATIENT; THROMBOCYTE COUNT; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BLOOD CLOTTING; DRUG EFFECTS; HEMOFILTRATION; HEMORRHAGE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROCEDURES; RISK FACTOR; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; CITRIC ACID; FEMALE; HEMOFILTRATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RISK FACTORS;

EID: 84862729459     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11403     Document Type: Article

References (35)

1. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007, 33:1563-1570. 10.1007/s00134-007-0754-4, 17594074.
2. Morabito S, Pistolesi V, Cibelli L, Pierucci A. Continuous renal replacement therapies (CRRT) will remain the most widely adopted dialysis modality in the critically ill. G Ital Nefrol 2009, 26:13-21.
3. Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010, 6:521-529. 10.1038/nrneph.2010.100, 20644583.
4. Mehta RL. Anticoagulation during continuous renal replacement therapies. ASAIO J 1994, 40:931-935.
5. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993, 43(Suppl 41):S237-S244.
6. Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL. Multicentre evaluation of anti-coagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005, 20:1416-1421. 10.1093/ndt/gfh817, 15855212.
7. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med 2006, 32:188-202. 10.1007/s00134-005-0044-y, 16453140.
8. Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009, 22:141-145. 10.1111/j.1525-139X.2008.00545.x, 19426417.
9. Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int 2001, 59:1510-1519. 10.1046/j.1523-1755.2001.0590041510.x, 11260415.
10. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000, 26:1652-1657. 10.1007/s001340000691, 11193272.
11. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003, 16:566-571.
12. Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2009, 2:439-447.
13. Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy - heparin or citrate?. Crit Care 2011, 15:202. 3222015, 21345279.
14. Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens 1999, 8:701-707. 10.1097/00041552-199911000-00009, 10630816.
15. Mariano F, Morselli M, Bergamo D, Hollo Z, Scella S, Maio M, Tetta C, Dellavalle A, Stella M, Triolo G. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011, 26:3882-3888. 10.1093/ndt/gfr106, 21385861.
16. Fall P, Szerlip HM. Continuous renal replacement therapy: cause and treatment of electrolyte complications. Semin Dial 2010, 23:581-585. 10.1111/j.1525-139X.2010.00790.x, 21166876.
17. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001, 60:370-374. 10.1046/j.1523-1755.2001.00809.x, 11422774.
18. Morabito S, Guzzo I, Solazzo A, Muzi L, Pistolesi V, Pierucci A. Acute renal failure following cardiac surgery. G Ital Nefrol 2006, 23(Suppl 36):S52-S60.
19. Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006, 48:806-811. 10.1053/j.ajkd.2006.07.016, 17060000.
20. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004, 30:260-265. 10.1007/s00134-003-2047-x, 14600809.
21. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005, 67:2361-2367. 10.1111/j.1523-1755.2005.00342.x, 15882280.
22. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007, 20:602-608.
23. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011, 26:232-239. 10.1093/ndt/gfq575, 20876598.
24. Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012, 38:20-28. 10.1007/s00134-011-2438-3, 22124775.
25. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. VA/NIH Acute Renal Failure Trial Network Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359:7-20. 2574780, 18492867, VA/NIH Acute Renal Failure Trial Network.
26. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 2004, 97:c131-c136. 10.1159/000079171, 15331942.
27. Park JS, Kim GH, Kang CM, Lee CH. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med 2011, 26:68-75. 10.3904/kjim.2011.26.1.68, 3056258, 21437165.
28. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009, 37:545-552. 10.1097/CCM.0b013e3181953c5e, 19114912.
29. Bihorac A, Ross EA. Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition. Am J Kidney Dis 2005, 46:908-918. 10.1053/j.ajkd.2005.08.010, 16253732.
30. Brain M, Parkes S, Fowler P, Robertson I, Brown A. Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 2011, 13:72-81.
31. Brandl M, Strobl K, Hartmann J, Kellner K, Posnicek T, Falkenhagen D. A target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapies. Blood Purif 2011, 33:7-20.
32. Mariano F, Triolo G. Anticoagulation of extracorporeal circuit in critically ill patients. G Ital Nefrol 2007, 24:34-42.
33. Mariano F, Tedeschi L, Morselli M, Stella M, Triolo G. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med 2010, 36:1735-1743. 10.1007/s00134-010-1909-2, 20480135.
34. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006, 1:79-87.
35. Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009, 37:2018-2024. 10.1097/CCM.0b013e3181a00a92, 19384210.